Clinical Trial Update: The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating first-line Lazertinib combined with locally ablative radiotherapy for patients with synchronous oligo-metastatic EGFR-mutant non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lazertinib (lazertinib)

Snippet

Sponsor: Yonsei University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN